The quality of starting chemical matter is key to determining the trajectory of success of a drug discovery project. High quality leads frequently advance more quickly to and through lead optimisation and prove more robust to failure in clinical development. Therefore, the selection of a high-quality starting point is a decision with long-lasting and potentially high-value consequences.
Our medicinal and computational chemists and compound management experts can work with you to design, cost-effectively source and format custom sets from the millions of compounds available in supplier databases.
We can work with you to select the right starting library for your target, combining one or more of the following approaches as best fits your project:
Screening-based approaches (utilising our in-house diversity and fragment libraries, or sourcing and plating alternative screening libraries)
Knowledge based approaches (e.g. target or structure based approaches)
Iterative screening approaches (where results from an initial screen of a subset of the library are used to guide the selection of second and subsequent sets)
Whichever approach is taken, the selection and assembly of a bespoke compound set for a specific screen will likely require the cross-discipline expertise that BioAscent can provide, including:
Computational and medicinal chemistry-driven compound selection.
Support from compound suppliers and expert aggregators. The logistics of using multiple suppliers can be daunting, given that the formats that compounds will be supplied in, delivery times and availability will vary.
Compound aggregation and management support. Once compounds arrive, they may need to be dissolved, aggregated and formatted into suitable plates to enable testing.
Opportunity Knocks: why high quality leads matter. Drug Discovery World, Fall 2021, Volume 21, Issue 4. P.Jones View article.
Director of Chemistry
Chief Operating Officer and Co-founder
Associate Director, In Silico Discovery and Data Analysis
Associate Director of Chemistry
Chief Scientific Advisor
Let's talk about how we can maximise your drug discovery success.